PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo (Q46366046)

21 December 2017

title

PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo (English)

1 reference

21 December 2017

author

Maria Thomas

2

1 reference

21 December 2017

Mikko Niemi

5

1 reference

21 December 2017

Ulrich M. Zanger

7

object named as

Ulrich M Zanger

1 reference

21 December 2017

author name string

Kathrin Klein

1

1 reference

21 December 2017

Stefan Winter

3

1 reference

21 December 2017

Andreas K Nussler

4

1 reference

21 December 2017

Matthias Schwab

6

1 reference

21 December 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

21 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

21 December 2017

volume

91

1 reference

21 December 2017

issue

6

1 reference

21 December 2017

page(s)

1044-1052

1 reference

21 December 2017

Pharmacogenomics: translating functional genomics into rational therapeutics

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Pharmacogenomics and individualized drug therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Summary of information on human CYP enzymes: human P450 metabolism data

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Drugs as CYP3A probes, inducers, and inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

The human CYP3A subfamily: practical considerations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Cytochrome P450 3A and their regulation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Transcriptional regulation and expression of CYP3A4 in hepatocytes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Sex is a major determinant of CYP3A4 expression in human liver

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Clinical implications of CYP3A polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

The missing linkage: what pharmacogenetic associations are left to find in CYP3A?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Genetic predictors of interindividual variability in hepatic CYP3A4 expression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a huge review

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

PPARalpha: energy combustion, hypolipidemia, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

PPARs Mediate Lipid Signaling in Inflammation and Cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Inferring statin-induced gene regulatory relationships in primary human hepatocytes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Interplay of pregnane X receptor with other nuclear receptors on gene regulation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

A note on exact tests of Hardy-Weinberg equilibrium

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.336

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.336

1 reference

21 December 2017

PubMed ID

22510778

1 reference

21 December 2017